DBV Technologies presented additional data from its Phase 3 VITESSE study at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2026 Annual Meeting in Philadelphia. The study evaluated the VIASKIN® Peanut Patch in children aged 4 to 7 and met its primary endpoint, with a 46.6% responder rate in the patch arm versus 14.8% in the placebo arm, a statistically significant difference (p < 0.001). The responder rate exceeded the prespecified threshold of 15% and was consistent across baseline eliciting dose strata and study populations.
Dr. Pharis Mohideen, Chief Medical Officer, noted that the data support the patch’s ability to induce desensitization in a broad patient cohort and reinforce the company’s plan to file a Biologics License Application in the first half of 2026. The results also confirm the effectiveness of the redesigned patch that addressed adhesion issues identified in earlier regulatory submissions.
The successful topline data de‑risk the VIASKIN® Peanut program and position DBV for a priority review under the FDA’s Breakthrough Therapy Designation. A timely BLA filing will enable the company to move toward commercial launch and expand treatment options for the 1.5 million children in the United States with peanut allergy.
The VITESSE results triggered an acceleration of warrant exercise periods, potentially adding up to $181 million in new capital. The infusion of capital is intended to fund working capital, BLA preparation, and launch readiness, extending the company’s operational runway for at least 12 months and reducing reliance on external financing.
In the broader market, the VIASKIN® Peanut Patch offers a non‑invasive alternative to oral immunotherapy such as Palforzia and IgE‑blocking therapy Xolair. EPIT technology delivers allergen through the skin, providing a unique mechanism that could improve patient adherence and safety. The data strengthen DBV’s competitive position and support a larger addressable market for peanut allergy treatment.
The company’s regulatory history—previously withdrawing a 2018 submission and receiving a Complete Response Letter in 2020—highlights the significance of the current data. The redesign of the patch and the robust Phase 3 results demonstrate DBV’s ability to overcome past challenges and advance toward FDA approval. Investors view the announcement as a positive step toward a potentially transformative product in a high‑need therapeutic area.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.